OCP-TAP approves Adtran’s OSA 5400 TimeCard™ for precise, resilient data center timing
Adtran today announced that the Open Compute Project (OCP) Time Appliance Project (TAP) has approved its OSA 5400 TimeCard™ for data center timing and synchronization. The pluggable device injects Adtran’s Oscilloquartz timing technology into any white box server, solving key challenges in the transition to virtualized environments. The OCP-TAP’s endorsement means data center operators leveraging the OSA 5400 TimeCard™ to synchronize COTS hardware can be assured of precise, reliable and robust timing as they move to more cost-efficient and scalable network architectures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230928894327/en/
The OSA 5400 TimeCard™ represents a simple route to accurate, reliable and robust data center timing. (Photo: Business Wire)
“We’re pleased to be able to announce that Adtran’s OSA 5400 TimeCard™ now supports the OCP-TAP driver. It’s an important milestone in our collective quest to advance robust and accurate timing solutions for distributed system use cases. By meeting our framework’s specifications, Adtran is helping us drive standardization and interoperability, accelerating the industry’s shift to open, standardized hardware,” said Ahmad Byagowi, TAP project leader at OCP-TAP. “This pluggable solution represents a simple route to accurate, reliable and robust data center timing. We believe that solutions like the OSA 5400 TimeCard™ will play a pivotal role in advancing the next generation of scalable and resilient infrastructure.”
Enabling data center operators to efficiently host the most demanding time-sensitive applications, Adtran’s OSA 5400 TimeCard™ plugs into any free PCIe slot to turn a standard COTS server into a precise PTP grandmaster clock or NTP server. With multiple oscillator options, the solution ensures accurate timing even during extended periods of GNSS disturbances. In combination with Adtran’s Ensemble Sync Director, the OSA 5400 TimeCard™ provides operational teams with a comprehensive, unified view of their entire timing infrastructure. This enables them to easily manage all elements of their timing network, enhancing control and reliability. What’s more, the OSA 5400 TimeCard™ has been developed to align fully with the IEEE P3335 standardization, ensuring adaptability and underscoring Adtran’s commitment to industry advancement in a cohesive digital ecosystem.
“We’re proud that our OSA 5400 TimeCard™ has been validated by OCP-TAP. This card brings our 74 years of expertise in timing and synchronization to standard servers, going beyond the TAP specifications to provide a scalable, fully featured timing solution in a compact half-size PCIe card. It offers a major boost for data center operators looking to embrace open, disaggregated hardware, especially where timing is vital and space is limited. Our OSA 5400 TimeCard™ ensures seamless, efficient operation of mission-critical and time-sensitive applications,” commented Igal Pinhasov, VP of PLM at Oscilloquartz, Adtran. “As the industry progresses towards agile, cost-effective data center environments, our pluggable timing technology will play a defining role in shaping future architectures.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230928894327/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
